- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04847505
68Ga-DOTA-TATE PET/CT Imaging in NETs
Pragmatic Study on the Use of 68Ga-DOTA-TATE PET|CT Imaging as a Standard of Care to Influence Clinical Management
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Stephanie Dubreuil
- Phone Number: 16617 819-346-1110
- Email: Stephanie.dubreuil2@usherbrooke.ca
Study Locations
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Recruiting
- CHUS
-
Principal Investigator:
- Éric Turcotte, MD
-
Contact:
- Stephanie Dubreuil
- Phone Number: 16617 819-346-1110
- Email: Stephanie.dubreuil2@usherbrooke.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinical requisition for a 68Ga-DOTA-TATE PET/CT signed by a referring doctor
- Patients with suspected or proven tumors expressing somatostatin receptors
- Informed consent by patient (or parents if patient is less than 18 years of age)
Exclusion Criteria:
- *Pregnancy (not an absolute exclusion). See below*.
- Patient refusal to participate.
Prior severe anaphylactic reaction to DOTA-TATE or somatostatin analogs.
In the case of a diagnostic procedure in a patient who is or may be pregnant, the principle of benefits-disadvantages would be applied following an in-depth discussion with the treating physicians and the patient. In this context, any clinical situation in which the patient's life would be at stake by excluding her from the study would be considered. The conditions to decide whether to include the patient would be:
- Severe medical condition involving the life of the pregnant woman and/or the fetus;
- Existing treatments that are ineffective or may present toxicity to the woman and/or fetus;
- High clinical suspicion of a somatostatin receptor overexpressing tumour;
- Negative, indeterminate or contraindicated first-line imaging tests;
- Therapeutic gesture considered during pregnancy based on the results of the examination, which may include termination of pregnancy or premature delivery;
- Documented discussion with the treating team and the patient;
- Patient agrees.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neuroendocrine cancer patients
All neuroendocrine cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with 3 MBq/kg (maximum 370 MBq) of 68Ga-DOTA-TATE. 45-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician. Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed. |
The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET/CT image acquisition.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety profile of 68Ga-DOTA-TATE
Time Frame: 5 years
|
Following the injection, the patient will be explicitly reminded of possible symptoms and undesirable events. The patient will be advised to inform the study personnel of the occurrence of any events, at the most opportune time. The patient will be instructed to call the local nuclear medicine study coordinator for any undesirable event that may occur for 48 hours after the PET/CT scan. Safety will be assessed by compiling all reported adverse events. Adverse events reported by patients or observed by the investigator will be recorded in the patients' CRFs, the AE database, and reported to the research manager. |
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Generate clinical information on the impact of 68Ga-DOTA-TATE for NET patient management
Time Frame: 5 years
|
Neuroendocrine tumors (NET) used to be difficult to diagnose early with conventional methods, but with the advent of new-generation Somatostatin Receptor radioligands such as 68Ga-DOTA-TATE precise and early detection is now frequent.
This trial offers the opportunity to evaluate the impact of this state-of-the-art diagnostic procedure on the management of NET patients on a large, nation-wide cohort.
As such, the research team will monitor the clinical gain of 68Ga-DOTA-TATE on the diagnostic and management of NETs regarding sensitivity, specificity and accuracy compared to previous diagnostic methods.
|
5 years
|
Instigate the routine standard-of-care use of 68Ga-DOTA-TATE for NET patients
Time Frame: 5 years
|
Clinical and scientific evidences showed that 68Ga-DOTA-TATE is vastly superior as a diagnostic tool than the current standard-of-care Octreoscan.
As such, this trial aims to implement 68Ga-DOTA-TATE as the new standard-of-care for precision diagnostic of NETs.
In order to do so, health policy agencies (most notably Health Canada) will be notified about the gains (or the flaws if any) of 68Ga-DOTA-TATE over the current standard-of-care (Octreoscan) for the precise diagnostic and follow-up of NETs that will be observed during the present study.
The safety profile and diagnostic accuracy assessed in Outcome 1 and 2 will be used to convince the authorities of the net benefit of using this procedure rather than the "old" standard-of-care.
|
5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Éric E Turcotte, MD, Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIMS-2019-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumors
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingNeuroendocrine Tumors,GastroenteropancreaticTaiwan
-
Grupo Espanol de Tumores NeuroendocrinosActive, not recruitingNeuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorSpain
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
Australasian Gastro-Intestinal Trials GroupCompletedMidgut Neuroendocrine Tumours | Pancreatic Neuroendocrine TumoursAustralia
-
Francesco De CobelliCompleted
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingNeuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine TumorsUnited States
-
University Hospital, Basel, SwitzerlandSwiss National Science Foundation; Paul Scherrer Institute (PSI)RecruitingNeuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)Switzerland
Clinical Trials on 68Ga-DOTA-TATE
-
Novartis PharmaceuticalsEckert & Ziegler Radiopharma GmbHRecruiting
-
Andrei IagaruNo longer availableCarcinoid Tumors | Islet Cell (Pancreatic NET) | Other Neuroendocrine TumorsUnited States
-
Wuhan Union Hospital, ChinaRecruitingNeuroendocrine Tumors | Osteomalacia | PET / CT | PET / MRChina
-
Peking Union Medical College HospitalRecruitingNeuroendocrine TumorsChina
-
Instituto Nacional de Cancerologia, ColumbiaCompleted
-
Peking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)Unknown
-
The First Affiliated Hospital of Xiamen UniversityRecruiting177Lu-DOTA-FAPI | 68Ga-DOTA-FAPI | TheranosticChina
-
Medical University InnsbruckNovartisCompletedNeuroendocrine TumorsAustria
-
AHS Cancer Control AlbertaCross Cancer InstituteActive, not recruiting
-
Peking Union Medical College HospitalNot yet recruiting